Navigation Links
Nouveau Life Pharmaceuticals (NOUV) In Talks with International Mass Distribution Firms
Date:7/2/2012

FORT LAUDERDALE, Fla., July 2, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, announced today that the Company is in talks with international mass distribution firms.  

Nouveau Life is in talks with mass distributors in Canada and the UK to sell the Nouveau Life's products in those markets.

"The distribution firms with which we are speaking are well-regarded in their respective countries," stated Nouveau Life CEO Melissa Walker. "These distributors have extensive knowledge of the regulatory requirements in each country. They know how to navigate their governments' oversight systems and will help Nouveau Life in the licensing processes. They also have well-established sales networks in place. These are growing markets. We see great potential for Nouveau Life to penetrate these markets." 

Seventy-one percent of Canadian adults report using a natural health product, with 38 percent reporting they use at least one daily. Canada requires that dietary supplements be licensed prior to market entry. The Natural Health Products Directorate (NHPD), a branch of Health Canada, is responsible for granting licenses for dietary supplements.

In the UK, the dietary supplement and vitamins market is valued at over $1.1 billion (U.S.). The government agency National Health Services (NHS) is responsible for regulating and licensing dietary supplements in the UK.

Nouveau Life currently sells four specialty supplements: Azul Instant™, Azul: Male Enhancer™, New Life Naturals: For Her Senses™, and New Life Naturals: For Your Weight Loss. The Company has plans to release another four products to the public in the coming weeks. All of Nouveau Life's supplements can be purchased by visiting www.nlpnaturals.com.

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993

 

 

 


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program
2. Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
3. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
6. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
7. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
8. Pharmaceuticals: Global Industry Almanac, MarketLine
9. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
10. Trading Of Onyx Pharmaceuticals Common Stock Halted
11. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ... into a settlement agreement with the United States ... SEC,s investigation into possible violations of the Foreign ... the settlement agreement, SciClone has agreed to pay ... interest and a penalty.  This payment is in ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... US ... Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio ... seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses ...
(Date:2/5/2016)... ... 2016 , ... Give To Cure today announced that it is ... Give To Cure’s campaign that is crowdfunding clinical trials to help find cures faster ... through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... Pekin, IL (PRWEB) , ... February 05, 2016 , ... ... in disguised form as a dream. A hallmark feature of patients with eating disorders ... and needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):